Tolga Tanguler
Executive VP & Chief Commercial Officer
Good morning, everyone, and thank you for joining us today. I’m Tolga Tanguler, Chief Commercial Officer at Alnylam, and I’m thrilled to be hosting today’s webinar to update you on our leadership journey in delivering transformative therapies for patients living with ATTR amyloidosis.
This past Friday marked one year since AMVUTTRA was approved in the U.S. for patients with ATTR cardiomyopathy, a pivotal milestone for Alnylam that has launched us into a new era of growth. We’ve built a strong foundation through years of disciplined execution and are rapidly advancing toward leadership in TTR. So how do we get here? In 2018, with ONPATTRO, we introduced an entirely new class of medicine, RNAi therapeutics that silence disease at its source, bringing a transformative option to patients with hereditary ATTR amyloidosis with polyneuropathy.
We have continued to build on that foundation with AMVUTTRA, which launched in ’22 for the same indication. And exactly 1 year ago, we expanded into ATTR cardiomyopathy population, which while still an orphan indication, is far more prevalent than hATTR-PN. We’re now driving strong adoption across that larger patient base, and we’re just getting started. We continue to accelerate AMVUTTRA uptake across the world. We’re advancing our next-generation TTR therapy, nucresiran, with the potential to further raise the bar.
And as announced today, we’re investing in cutting-edge capabilities to enable earlier diagnosis, better coordinated care and sustained long-term outcomes for patients. The strategy is clear: lead with science, reach patients still untreated or progressing on stabilizers and deliver durable impact
